LabCorp Completes Tender Offer for Orchid Cellmark | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Laboratory Corporation of America today said that it has successfully completed its cash tender offer for all outstanding shares of Orchid Cellmark.

It also announced the commencement of a subsequent offering period to expire on Dec. 15, 4:00 p.m. EST.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

An opinion piece in the New York Times urges lawmakers to keep genetic protections in place.

Research funding in Canada is to remain mostly the same, ScienceInsider reports.

In Science this week: random DNA replication errors play role in cancer, and more.

The Bill and Melinda Gates Foundation embarks on an open-access publishing path.